COCP Stock: Cocrystal Pharma, Inc. Stock Price, Analysis & Insights
Get live cocp stock price $1.58, comprehensive Cocrystal Pharma, Inc. stock analysis, charts, news, and expert forecast. Real-time cocp stock data and investment insights.
Company Overview
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Company Information
- CEO
- Sam Lee
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
Contact Information
- Address
- 19805 North Creek Parkway
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 16.19M market capitalization
- Trading Volume: 82.78M shares traded today
- Price Range: 52-week range of $1.12 - $3.26
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. (COCP) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 16.19M, the company represents a significant player in its market. The stock is currently trading at $1.58 with a positivedaily change of 9.72%.
The company's 11 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.27, beta of 2.28, and 52-week price range from $1.12 to $3.26when evaluating investment opportunities.
Why Invest in Cocrystal Pharma, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Sam Lee
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.